 Home > Active Ingredient News > Antitumor Therapy > WCLC 2020: Datopotamab deruxtecan and Enhertu show promising clinical activity in patients with advanced non-small cell lung cancer

WCLC 2020: Datopotamab deruxtecan and Enhertu show promising clinical activity in patients with advanced non-small cell lung cancer

 Last Update: 2021-02-03
 Source: Internet
 Author: User

Tags

makeup cause cancer

congress

aspartame cause cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Lung cancer is the leading cause of cancer death, accounting for about one-fifth of all cancer deaths worldwide, of which 80-85% are classified as non-small cell lung cancer (NSCLC).
patients with metastasis, the prognosis was particularly poor, with only 6-10% of patients surviving within five years of diagnosis.
currently, there is no approved anti-NSCLC therapy targeting TRP2 or HER2.
latest data from AstraZeneca and AstraZeneca's Datapotamab deruxtecan (Dato-DXd; DS-1062) and Enhertu (Curto-Pearl monoantixtecan) show that both antibody drug conjugations (ADCs) have encouraging results for patients with late-stage NSCLC.
data were released during the World Lung Cancer Congress (WCLC).
results from the TRTPION-PanTumor01 Phase I trial showed good clinical activity in patients with late-stage or metastasis NSCLC targeting TRAP2.
addition, the results of the DESTINY-Lung01 Phase II clinical trial showed that metastasis NSCLC patients using Enhertu, which targeted HER2, had preliminary evidence of tumor resistance in HER2 over-expression queues.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

High Quality Resveratrol 99% powder 501-36-0 Shaanxi Dideu Medichem Co.Ltd

CAS No.: 501-36-0

Chemical Grade

$1/KG FOB

High purity Epirubicin hydrochloride 98% with best price 56390-09-1 and Epirubicin hydrochloride raw powder

CAS No.: 56390-09-1

Pharmacy Grade

$8.8-10/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.